Report of Foreign Issuer (6-k)
November 18 2016 - 5:20PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 6-K
REPORT OF
FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the month of November 2016
Commission File Number: 001-31995
MEDICURE
INC.
(Translation of registrant's name into English)
2-1250 Waverley Street
Winnipeg, MB Canada R3T 6C6
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x
Form 40-F o
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
Indicate by check mark whether the registrant
by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule
12g3-2(b) under the Securities Exchange Act of 1934.
Yes o
No x
If “Yes” is marked, indicate below
the file number assigned to the registrant in connection with Rule 12g3-2(b): 8a72____.
EXHIBIT
LIST
Exhibit |
Title |
|
|
99.1 |
News Release Dated November 18, 2016 - Medicure to Hold Investor Call on November 21, 2016 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Medicure Inc. |
|
(Registrant) |
|
|
|
|
|
Date: November 18, 2016 |
By: |
/s/ Dr. Albert D. Friesen |
|
Dr. Albert D. Friesen |
|
Title: President & CEO |
Exhibit 99.1
Medicure to Hold Investor Call on November 21, 2016
WINNIPEG, Nov. 18, 2016 /CNW/ - Medicure Inc. ("Medicure")
(TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, will hold a conference call and webcast regarding the November 18, 2016
announcement surrounding the option exercise to acquire a majority interest in Apicore and the related debt transaction on Monday,
November 21, 2016, at 10:30 AM Central Time (11:30 AM Eastern Time).
Conference Call Info:
Topic: Acquisition of Majority Interest in Apicore
Call date: Monday, November 21, 2016
Time: 10:30 AM Central Time (11:30 AM Eastern Time)
Canada toll-free: 1 (888) 465-5079 (Canada
Toll: 1 (416) 216-4169)
United States toll-free: 1 (888) 545-0687
Passcode: 7552479#
Webcast: This conference call will be webcast live over the
internet and can be accessed from the Medicure investor relations page at the following link: http://www.medicure.com/investors.html
You may request international country-specific access information
by e-mailing the company in advance. Management will accept and answer questions related to the financial results and operations
during the question-and-answer period at the end of the conference call. A recording of the call will be available following the
event at the company's website.
About Medicure Inc.
Medicure is a specialty pharmaceutical company focused on
the development and commercialization of therapeutics for the U.S. hospital market. The primary focus of the Company and
its subsidiaries is the marketing and distribution of AGGRASTAT (tirofiban HCl) for non-ST elevation acute coronary syndrome in the
United States, where it is sold through the Company's U.S. subsidiary, Medicure Pharma, Inc. For more information on Medicure
please visit www.medicure.com.
About Apicore
Apicore is a leading process R&D and API manufacturing
service provider for the worldwide pharmaceutical industry. Apicore offers a wide portfolio of services ranging from manufacture
of API's for the generic industry to custom synthesis for early phase pharmaceutical research, and branded products. Apicore has
2 FDA-approved facilities. In the U.S., the Somerset, New Jersey facility can produce a few grams up to 200 kg volumes and in India,
the Vadodara, Gujarat facility can produce a few kilograms up to 60 metric tons yearly. Both facilities are equipped with state-of-the-art
analytical and research capabilities. For more information, please visit Apicore online at www.apicore.com.
To be added to Medicure's e-mail list, please visit:
http://medicure.mediaroom.com/alerts
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy
of this release.
SOURCE Medicure Inc.
%CIK: 0001133519
For further information: James Kinley, Chief Financial Officer,
Tel. 888-435-2220, Fax 204-488-9823, E-mail: info@medicure.com, www.medicure.com
CO: Medicure Inc.
CNW 17:00e 18-NOV-16
This regulatory filing also includes additional resources:
ex991.pdf
Medicure (PK) (USOTC:MCUJF)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medicure (PK) (USOTC:MCUJF)
Historical Stock Chart
From Apr 2023 to Apr 2024